MR spectroscopy in neurodegenerative disease

Molecular Imaging and Biology

Volumn 9, Issue 4, 2007, Pages 196-203

  Martin, W R Wayne ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alzheimer's disease; Amyotrophiclateral scierosis; Magnetic resonance spectroscopy; Neurodegenerative disease; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; CELL MARKER; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROTRANSMITTER; PHOSPHATE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN SIZE; CHEMICAL ENVIRONMENT; DEGENERATIVE DISEASE; DIAGNOSTIC PROCEDURE; GLIA; HUMAN; IN VIVO STUDY; MAGNETIC FIELD; METHODOLOGY; MOLECULAR IMAGING; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW;

BRAIN; BRAIN CHEMISTRY; HUMANS; ISOTOPES; NEURODEGENERATIVE DISEASES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR;

EID: 34447100593     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0087-2     Document Type: Review

References (74)

1. Clark JF, Doepke A, Filosa JA, et al. 2006 N-acetylaspartate as a reservoir for glutamate Med Hypotheses 67 506-512
2. Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13:981-989
3. Matthews PM, Francis G, Antel J, Arnold DL (1991) Proton magnetic resonance spectroscopy for metabolic characterisation of plaques in multiple sclerosis. Neurology 41:1251-1256
4. Chong WK, Sweeney B, Wilkinson ID, et al. (1993) Proton spectroscopy of the brain in HIV infection: Correlation with clinical, immunologic and MR imaging findings. Radiology 188:119-124
5. Shino A. Matsuda M. Morikawa S. Inubushi T. Akiguchi I. Handa J. 1993 Proton magnetic resonance spectroscopy with dementia Surg Neurol 39 143-147
6. Gideon P, Henriksen O, Sperling B, et al. (1992) Early time course of N-acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 23:1566-1572
7. Cwik V, Hanstock C, Allen PS, Martin WRW (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72-77
8. Clark JB (1998) N-acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20:271-276
9. Vion-Dury J, Meyerhoff DJ, Cozzone PJ, Weiner MW (1994) What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurol 241:354-371
10. Allen PS, Thompson RB, Wilman AH (1997) Metabolite-specific NMR spectroscopy in vivo. NMR Biomed 10:435-444
11. 1H MRS using water as an internal standard. Magn Reson Imaging 11:107-108
12. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J (1993) Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology 187:219-227
13. Davie C (1998) The role of spectroscopy in parkinsonism. Mov Disord 13:2-4
14. Clarke CE, Lowry M (2001) Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes. Eur J Neurol 8:573-577
15. Holshauser BA, Komu M, Moller HE, et al. (1995) Localised proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: A multicenter pilot study. Magn Reson Med 33:589-594
16. Davie CA, Wenning GK, Barker GJ, et al. (1995) Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 37:204-210
17. Cruz CJ, Aminoff MJ, Meyerhoff DJ, Graham SH, Weiner MW (1997) Proton MR spectroscopic imaging of the striatum in Parkinson's disease. Magn Reson Imaging 15:619-624
18. Tedeschi G, Litvan I, Bonavita S, et al. (1997) Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 120:1541-1552
19. Clarke CE, Lowry M, Horsman A (1997) Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 12:297-301
20. Ellis CM, Lemmens G, Williams SCR, et al. 1997 Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa treated Parkinson's disease: A proton magnetic resonance spectroscopy study Neurology 49 438-444
21. Clarke CE, Lowry M, 2000 Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy Eur J Neurol 7 661-665
22. 1H magnetic resonance spectroscopy and MRI of Parkinson's disease Mov Disord 17 917-927
23. Oz G, Terpstra M, Tkac I, et al. (2006) Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: Detection of high GABA concentrations. Magn Reson Med 55:296-301
24. 1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients Neurol Sci 22 69-70
25. Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. (1999) Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: A proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 67:20-26
26. Camicioli RM, Korzan JR, Foster SL, et al. (2004) Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 354:177-180
27. Federico F. Simone I.L. Lucivero V. et al. 1999 Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes Ital J Neurol Sci 20 223-229
28. 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker J Neurol Neurosurg Psychiatry 75 103-109
29. 1H magnetic resonance spectroscopy of Parkinson disease patients J Magn Reson Imaging 16 13-20
30. Tofts PS, Wray S (1988) A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy. NMR Biomed 1:1-10
31. Pioro EP, Antel JP, Cashman NR, Arnold DL, 1994 Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo Neurology 44 1933-1938
32. Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL (2003) Gabapentin therapy for amyotrophic lateral sclerosis: Lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol 24:476-480
33. Kalra S, Genge A, Arnold D (2003) A prospective, randomized, placebo controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: Feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord 4:22-26
34. Abe K, Takanashi M, Watanabe Y (2001) Decrease in N-acetylaspartate/ creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 43:537-541
35. Kaufmann P, Pullman SL, Shungu DC, et al. (2004) Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 62:1753-1757
36. Cwik VA, Hanstock CC, Allen PS, Martin WRW (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72-77
37. 1H-MRSI. Neurology 58:773-779
38. Kalra S, Hanstock CC, Martin WRW, et al. (2006) Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol 63:1144-1148
39. Kalra S, Cashman NR, Genge A, Arnold DL (1998) Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9:1757-1761
40. Schuff N, Capizzano AA, Du AT, et al. (2002) Selective reduction of N-acetyl aspartate in medial temporal and parietal lobes in AD. Neurology 58:928-935
41. Jessen F, Block W, Traber F, et al. (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55:684-688
42. Frederick BD, Lyoo IK, Satlin A, et al. (2004) In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog Neuropsychopharm Biol Psychiatry 28:1313-1322
43. 1H MR spectroscopy in common dementias. Neurology 63:1393-1398
44. 1H MRS study. Neurology 57:626-632
45. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer FB (1989) Differences in the metabolism of inositol and phosphoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta 1004:169-179
46. Ross AJ, Sachdev PS, Wen W, Brodaty H (2006) Longitudinal changes during aging using proton magnetic resonance spectroscopy. J Gerontol A Biol Sci Med Sci 61A:291-298
47. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging 17:349-357
48. 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12:2315-2317
49. Kantarci K, Jack CR Jr, Xu YC, et al. (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease. Neurology 55:210-217
50. 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003:26-35
51. Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in Alzheimer's disease. Neurology 56:592-598
52. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 384:23-28
53. Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probably Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162:667-675
54. Falini A, Bozzali M, Magnani G, et al. (2005) A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 26:1159-1163
55. Marjanska M, Curran GL, Wengenack TM, et al. (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102:11906-11910
56. Dedeoglu A, Choi J-K, Cormier K, Kowall NW, Jenkins BG (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012:60-65
57. von Kienlin M, Kunnecke B, Metzger F, et al. (2004) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18:32-39
58. DiMauro S, (1993) Mitochondrial involvement in Parkinson's disease: The controversy continues. Neurology 43:2170-2171
59. Gu M, Cooper JM, Taanman JW, Schapira AHV (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44:177-186
60. Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, Arnold DL (1991) In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 41:114-120
61. Penn AMW, Roberts T, Hodder J, Allen PS, Zhu G, Martin WRW (1995) Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45:2097-2099
62. Rango M, Bonifati C, Bresolin N (2006) Parkinson's disease and brain mitochondrial dysfunction: A functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26:283-290
63. Fox PT, Raichle ME, Mintun MA, Dence C (1988) Nonoxidative glucose consumption during focal physiologic neural activity. Science 241:462-464
64. Barbiroli B, Martinelli P, Patuelli A, et al. (1999) Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 14:430-435
65. 18FDG-PET study. Brain 123:340-352
66. 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 50:1033-1040
67. 31P spectroscopy study. Psychopharmacology (Berl) 180:359-365
68. 1H NMR spectroscopy. Neurology 43:2689-2695
69. 13C-MRS to research on brain metabolism. NMR Biomed 16:303-312
70. 13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed 16:339-357 339-357
71. 13C NMR spectroscopy of the brain. NMR Biomed 16:313-338
72. Hyder F, Patel AB, Gjedde A, Rothman DL, Behar KL, Shulman RG (2006) Neuronal-glial glucose oxidation and glutamatergic-GABAergic function. J Cereb Blood Flow Metab 26:865-877
73. 13C magnetic resonance spectroscopy study. MAGMA 16:29-42
74. 1H spectra with LCModel. NMR Biomed 14:260-264